Zymeworks INC 8-K filings

Zymeworks announced its first quarter 2024 financial results, highlighting a cash runway into the second half of 2027 and progress in its clinical programs.

Zymeworks Inc. has announced the departure of its Chief Financial Officer, Dr. Christopher Astle, effective March 31, 2024, and detailed the terms of his separation agreement.

Zymeworks Inc. has removed its Chief Financial Officer, Dr. Christopher Astle, and appointed current CEO Kenneth Galbraith as interim CFO, effective immediately.

Zymeworks Inc. has appointed Dr. Neil Gallagher to its board of directors, effective April 2, 2024, to bolster its governance and drug development expertise.

Zymeworks announced its full year 2023 financial results, highlighting a strong cash position and progress in its clinical development programs, including the initiation of a rolling BLA submission for zanidatamab.

Zymeworks has appointed Scott Platshon of EcoR1 to its board of directors and provided details on a previously announced $50 million pre-funded warrant transaction with EcoR1.

Zymeworks has appointed Dr. Alessandra Cesano to its board of directors, effective February 8, 2024, succeeding Dr. Kenneth Hillan, who resigned.